Does Anthem Cover Wegovy, Ozempic or Zepbound for Weight Loss?

Anthem pays for Wegovy (pen or pill), Zepbound or Foundayo, a daily GLP-1 tablet, for weight loss only when your plan's benefits include weight-loss drugs.^{1, 2, 3, 4} Even then, it generally requires prior authorization, Anthem's approval before the pharmacy can fill the prescription.^{1, 3} Its September 2026 criteria usually ask for 6 months in a provider-supervised diet and exercise program first.^{3, 5, 6} That step is skipped for a body mass index (BMI) of 40 or more, heart failure rated class III or IV, or moderate to severe sleep apnea.^{3, 5, 6}

• Through work: on Anthem's standard employer drug lists, current as of August 1, 2026, all three carry a "BE" flag for a possible benefit exclusion, so coverage depends on your employer's plan.¹ Anthem's Select lists for small-employer plans don't include them at all.^{7, 8, 9} How to tell which list is yours.
• Bought yourself: none of the three is on any Anthem individual drug list for 2026 or 2027.^{10, 11} Individual plans.
• Ozempic or Mounjaro: Anthem approves them for documented type 2 diabetes, not for weight loss or prediabetes.¹² Anthem's diabetes criteria.
• Anthem Medicare Advantage: federal law leaves weight loss out of the standard Medicare drug benefit, so these plans generally don't pay for it unless a plan adds it as an extra benefit.^{13, 14, 15} Medicare's separate GLP-1 Bridge can, for a $50 monthly copay if you qualify.¹⁶ Medicare.
• Anthem Medicaid: your state's rules decide, and they differ a lot.^{17, 18} Medicaid.

Whatever your plan, the six checks further down show how to get a firm answer for it. If Anthem has already denied coverage, see appeal rights by plan type; if your plan leaves these drugs out, see what they cost without coverage.

Which Anthem plan is on your card

Anthem Blue Cross and Blue Shield plans are part of Elevance Health and are offered in 14 states; in California, the trade name is Anthem Blue Cross.^{19, 20} Anthem's companies are independent licensees of the Blue Cross and Blue Shield Association, so the plan rules on this page come from Anthem's own documents, not other Blue Cross companies'.²¹ If your card names a different Blue Cross Blue Shield company, check that company's drug list. If it says Ambetter, the plan comes from Centene, a different insurer; see our Ambetter page.²²

Also check two details:

• The state your plan is based in. Anthem posts drug lists by state and tells members to use the list for the state where the plan is located, even if they live elsewhere.²³
• "HealthKeepers" in Virginia. Anthem HealthKeepers is Anthem's HMO coverage in Virginia, offered by its affiliate HealthKeepers, Inc., so check it like any other plan through work or bought yourself.²¹ Anthem HealthKeepers Plus, from the same company, is Virginia Medicaid coverage with its own rules (see Medicaid).¹⁸

Plans through work: the BE flag on Anthem's drug lists

Anthem's drug lists mark each drug with short codes. On the standard employer lists, current as of August 1, 2026, the Wegovy pen, the Wegovy pill, Wegovy HD (the 7.2 mg pen), Zepbound and Foundayo all sit on tier 2 with three notes: PA, BE and QL. The key printed in the lists explains them:¹

• Tier 2 drugs cost you more than tier 1 drugs. What you pay depends on the tier and your plan's benefit.¹
• PA is prior authorization. You may need benefits approved before the prescription can be filled.¹
• QL is a quantity limit, a cap on how much medicine is covered in a set time.¹
• BE is benefit exclusion. The drug may not be covered, depending on your plan's design; Anthem's drug search gives weight loss as an example of a use a plan might not cover.^{1, 2}

Ozempic and Mounjaro get PA and QL with no BE flag (see Ozempic and Mounjaro).¹ The BE flag also sits on every other weight-loss medicine these lists include, such as the older pills phentermine and orlistat and generic liraglutide for weight management. So a plan that leaves out weight-loss drugs leaves those out too.¹ Each of these medicines has its own label; NIDDK, part of the National Institutes of Health, says serious side effects are rare but can happen, and that none should be taken during pregnancy or when planning one.²⁴

We checked the employer lists linked from Anthem's 14 state drug-list pages on October 3, 2026, apart from three written for single named employers. The codes above are the same on the 21 standard lists (seven list types, each in 3-, 4- and 5-tier versions) and on Anthem's California, Connecticut, New York and Virginia versions of them, with these exceptions:^{25, 26, 27}

• Small employers. Anthem posts separate Select drug lists for small-group plans, and says its National and Traditional Open lists apply to small-group coverage only "in some cases."^{25, 26} Wegovy, Zepbound and Foundayo appear on none of the 73 Small Group Select lists Anthem posts for 2025, 2026 and 2027 plans, the same as on the individual lists below.^{7, 8, 9}
• A rare-disease drug. Imcivree (setmelanotide), which is approved only for obesity from certain rare genetic conditions or from damage to the hypothalamus (acquired hypothalamic obesity), has no BE flag on seven California, Connecticut and New York versions dated September 1, 2026 or January 1, 2027.^{28, 29, 30, 31}
• California fully insured plans. Anthem Blue Cross also posts versions of its Essential and National lists for fully insured plans, where Anthem rather than the employer pays the claims. Each version is for plans regulated by either California's Department of Managed Health Care (DMHC) or its Department of Insurance (CDI), and your benefits booklet says which.^{20, 26, 32, 33} On the versions current as of September 1, 2026, Wegovy and Foundayo aren't listed, and Zepbound's single-dose pen is on tier 3 with prior authorization. The DMHC versions also list the Zepbound KwikPen (one pen holding four weekly doses), on tier 2 with only the BE flag.^{20, 32, 34} They put BE on both Zepbound entries and every other weight-loss medicine except Imcivree; the CDI versions put it on none of them.^{20, 32}
• Two special lists. The National Closed list includes the Wegovy pill but neither Wegovy pen. The Generic Premium list, which Anthem no longer markets, has no Wegovy, Zepbound or Foundayo; its only weight-loss medicines are generic liraglutide and orlistat, both with PA, BE and QL.^{25, 35, 36}
• Older lists still posted. Connecticut's five lists for fully insured members in 2024 (current as of April 1, 2026) lack Foundayo and Wegovy HD. A California DMHC list dated April 2025 still shows the Wegovy pen and Zepbound with PA, BE and QL.^{37, 38, 39}

If you bought your own Anthem plan

Anthem's individual and family plans, bought on or off the Marketplace, use a Select drug list for each state.^{26, 27} We checked all 16 lists Anthem posts for 2026 (current as of October 1, 2026) and all 16 for 2027 (dated January 1, 2027, when those plans start); Maine and New York each post two versions.^{10, 11, 27, 40}

• Wegovy, Zepbound and Foundayo are on none of them. Anthem's booklets say a drug that isn't on your list may not be covered, and you may have to pay its full cost.^{10, 11}
• The Ozempic pen is on every one, with prior authorization; the Ozempic tablet is on none of them.^{10, 11}
• Mounjaro is missing from 4 states' 2026 lists and from 9 of the 14 states' 2027 lists.^{10, 11} If you take Mounjaro and are choosing an Anthem plan for 2027, look it up on your state's 2027 list before you enroll.

Anthem Medicare Advantage and Medicaid plans

Medicare Advantage

Anthem's Medicare plans with drug coverage are Medicare Advantage plans; it doesn't sell standalone Part D plans.⁴¹ Federal law leaves drugs used for weight loss out of the standard Part D benefit those plans include.^{13, 14} A plan can still cover these GLP-1s for other uses Part D allows, if they're on its drug list or the plan approves an exception your prescriber asks for:^{42, 45, 60}

• Type 2 diabetes.
• Moderate to severe obstructive sleep apnea (Zepbound).
• MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH), a form of fatty liver disease with inflammation and liver damage that can lead to scarring. Part D can cover the Wegovy pen for MASH with moderate to advanced scarring (stage F2 or F3) but not cirrhosis.^{43, 44}
• Lowering the risk of heart attack, stroke or cardiovascular death in adults with established cardiovascular disease and obesity or overweight (Wegovy).^{42, 44}

A Part D plan with enhanced coverage can also add drugs the law excludes, weight-loss drugs among them, as an extra (supplemental) benefit, so check your plan's list.^{15, 45} The one Anthem group Medicare plan whose 2026 criteria we could read covers Wegovy for MASH or established cardiovascular disease. It says weight-loss use without established cardiovascular disease may not be approved.⁴⁶ The one Anthem group Medicare Advantage drug list we could open doesn't include Zepbound.⁴⁷ Anthem's drug lists for its individual Medicare Advantage plans sit behind its plan finder, so we couldn't review them.

For weight reduction itself, Medicare's GLP-1 Bridge is a temporary CMS program that runs outside your Anthem plan through December 31, 2027. It covers Wegovy (injection or pill), Foundayo or the Zepbound KwikPen (one pen holding four weekly doses) for a $50 copay per monthly supply. It is for adults with Part D coverage who meet its BMI-based criteria and get prior authorization.^{16, 34, 42, 48} Some people are excluded, including anyone already getting a GLP-1 through Part D; see who qualifies for the Bridge and how to apply.⁴²

Medicaid

Anthem's Medicaid plans follow their state's rules, and two documents show how far apart those rules can be:

• California. Medi-Cal prescription coverage, for Anthem Blue Cross members too, runs through the state's Medi-Cal Rx program, which reviews drug approval requests.^{49, 50} Since January 1, 2026, Medi-Cal Rx no longer covers GLP-1 drugs taken for weight loss alone, Wegovy and Zepbound included. It says Wegovy stays covered for noncirrhotic MASH when the prescriber sends the diagnosis code, and that prescribers can ask for prior authorization for Wegovy for cardiovascular disease or Zepbound for sleep apnea. Weight-loss requests for members under 21 can still be approved through prior authorization.^{17, 49}
• Virginia. Anthem HealthKeepers Plus can approve Wegovy, Zepbound or Foundayo for weight loss under its September 2026 form, but only with a BMI over 40, or over 37 with high blood pressure, abnormal blood fats or type 2 diabetes.¹⁸ The form also requires a failed trial of a non-GLP-1 weight-loss medicine (unless none can be tolerated) and of the product Virginia's preferred drug list names. The prescriber must attest that the obesity is disabling and life-threatening. For a pill, Foundayo or the Wegovy pill, the form adds a medical reason the person can't use an injection, or failed trials of two injectable drugs.¹⁸ Approvals last 6 months, a renewal needs at least 5% more weight loss since the last approval, and renewals stop once BMI falls below 25.¹⁸

For other states, see how Medicaid programs handle GLP-1 drugs.

Six checks for your own Anthem plan

Only your plan's own records can settle the question. Anthem points members to two places, its Price a Medication tool and their plan documents, and these steps use both:^{1, 2}

1. Open the right drug list. On Anthem's drug list page, choose the state where your plan is based. If you aren't sure which list is yours, Anthem says to ask your employer or call the Pharmacy Member Services number on your ID card.²³
2. Price the drug. Sign in at anthem.com or in the Sydney Health app and use Price a Medication, which shows coverage details and prices at pharmacies near you.^{1, 51}
3. Read the exclusions. Your Certificate or Evidence of Coverage, or your Summary Plan Description, lists what the plan leaves out. At anthem.com it is under My Plan, then Benefits, then Plan Documents.¹ Look for wording about weight-loss drugs.
4. Ask your benefits office. On a plan through work, ask whether the plan includes weight-loss drugs and which Anthem drug list it uses.^{23, 52}
5. Call Pharmacy Member Services. Ask: "Does my plan exclude weight-loss drugs? If not, is Wegovy, Zepbound or Foundayo covered for my diagnosis, and which criteria apply?" Write down the date and the name of the person you spoke with.²³
6. Have your prescriber file. Anthem says electronic prior authorization is its preferred way for prescribers to send requests.²

What we could not check. We couldn't see any member's plan documents or Anthem's member-only prices, so this page can't tell you what your plan covers or what you would pay. We found no Anthem figures on copays, approval times or approval rates for these drugs.

If your plan covers weight-loss drugs: what Anthem asks for

Used with a reduced-calorie diet and more physical activity, Wegovy, Zepbound and Foundayo are FDA-approved for long-term weight reduction in adults with obesity, or with overweight and at least one weight-related health problem.^{4, 34, 44} The Wegovy pen, at doses up to 2.4 mg, is also approved for children 12 and older with obesity; Wegovy HD and the Wegovy pill are for adults only.⁴⁴ What their labels warn about is in the risk section below.

Even when a plan covers weight-loss drugs, Anthem's criteria for all three, dated September 16, 2026, ask for four things from adults:^{3, 5, 6}

1. A qualifying BMI from the last 90 days. A BMI of 30 or higher, or 27 or higher with a weight-related condition: high blood pressure, type 2 diabetes, abnormal blood fats (dyslipidemia), obstructive sleep apnea or cardiovascular disease.³
2. Six months in a supervised program first. At least 6 months in a lifestyle program supervised by a health care provider. Your records must show that during those months you kept to a calorie deficit of about 30% (roughly 500 calories a day below what your body uses). They must also show at least 150 minutes of exercise a week, unless a medical condition rules it out, and that you still lost less than 5% of your weight.^{3, 5, 6} Anthem skips this step for a BMI of 40 or higher, or for heart failure rated class III or IV on the New York Heart Association scale. It also skips it for sleep apnea with an apnea-hypopnea index (AHI, a sleep-study score) of 15 or more.^{3, 5, 6}
3. A program now. You must still be in a supervised lifestyle program when the request is made, and not taking two or more weight-loss medicines at once.³
4. A risk conversation on record. Your prescriber must have gone over the drug's risks, benefits, realistic expectations and the need for long-term follow-up with you.^{3, 5, 6}

Anthem's criteria say a request may not be approved in three cases: a BMI under 18.5; MEN 2 (multiple endocrine neoplasia syndrome type 2, an endocrine system condition) or a personal or family history of medullary thyroid carcinoma (MTC, a type of thyroid cancer); or use together with another GLP-1 drug.^{3, 5, 6, 34} Wegovy's criteria also have a separate section for teens 12 to 17, for the pen at doses up to 2.4 mg only.³ Each document says federal and state laws, contract language and plan programs can take precedence over it.^{3, 5, 6}

Wegovy for the heart or liver. With the same diet-and-activity condition, Wegovy is FDA-approved to lower the risk of heart attack, stroke or cardiovascular death in adults with established cardiovascular disease and obesity or overweight.⁴⁴ The Wegovy pen, not Wegovy HD, is also approved for adults with MASH who have stage F2 or F3 liver scarring and no cirrhosis. That is an accelerated approval: FDA granted it based on improvement in MASH and liver scarring, and keeping it may depend on a further trial confirming that patients benefit.⁴⁴

Anthem's Wegovy criteria cover both uses. The heart section needs a prior heart attack, a prior stroke or symptomatic peripheral artery disease, and a BMI of 27 or more. It also needs standard heart medicines and an A1C (a blood test of average blood sugar) under 6.5%, below the level Anthem's diabetes criteria use to confirm type 2 diabetes. The MASH section needs imaging or biopsy evidence and a supervised lifestyle program first.^{3, 12}

Only the weight-management sections of the Wegovy criteria open with the line "When member's benefit covers weight loss drugs and requires prior authorization," which the heart and MASH sections lack.³

Zepbound and sleep apnea. With the same condition, Zepbound is also FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity.³⁴ Anthem's Zepbound criteria have no separate sleep apnea section, though. Sleep apnea appears only inside the weight-management rules, as a qualifying condition and, at an AHI of 15 or more, as a way to skip the six-month program.⁵ We found no public Anthem document saying whether a plan that excludes weight-loss drugs still covers these heart, liver or sleep apnea uses, so ask Anthem before your prescriber files.

Anthem's approvals are time-limited:

Each row comes from Anthem's criteria for that drug.^{3, 5, 6, 12} Teens 12 to 17 on the Wegovy pen get 28 weeks, then 1 year, and a renewal needs a drop in BMI of more than 4% from the start.³ For the weight-loss approvals, renewal records must be from the last 90 days, and you must still be in the lifestyle program.^{3, 5, 6}

Ozempic and Mounjaro: type 2 diabetes only

Anthem approves Ozempic and Mounjaro only for confirmed type 2 diabetes, so weight loss or prediabetes alone doesn't qualify.¹² Ozempic and Wegovy both contain semaglutide, and Mounjaro and Zepbound both contain tirzepatide, but FDA approved each brand for different uses. Ozempic comes as a weekly pen and a daily tablet. Along with diet and exercise, Ozempic is approved to improve blood sugar in adults with type 2 diabetes, and Mounjaro in adults and children 10 and older with it.^{53, 54, 55} Neither is approved for weight loss, so using either one for that would be off-label, meaning outside its FDA-approved uses.^{53, 55}

Anthem's criteria for these drugs, dated September 14, 2026, approve them only when both of these are true:¹²

• Your records confirm type 2 diabetes, for example with an A1C of 6.5% or higher or a fasting blood sugar of 126 mg/dL or higher.¹²
• You tried metformin, a diabetes pill, and it didn't work or you couldn't tolerate it, or you can't take it for a medical reason. For Ozempic, a history of disease from clogged arteries, such as a heart attack, stroke or peripheral artery disease, can stand in for the metformin step. So can chronic kidney disease, for the Ozempic pen only.¹²

The criteria say these drugs may not be approved alongside Wegovy, Zepbound, Foundayo or another GLP-1 drug, or with a DPP-4 inhibitor, another kind of diabetes medicine.¹² With prediabetes, the route Anthem's documents describe is the weight-management criteria above, if your plan covers weight-loss drugs. Prediabetes isn't one of the conditions they list, so below a BMI of 30 you would need one that is.³ Medicare's GLP-1 Bridge does count prediabetes at a BMI of 27 or more.⁴²

The risk conversation Anthem asks for, drug by drug

Anthem's weight-loss criteria for Wegovy, Zepbound and Foundayo want a record that your prescriber went over the drug's risks with you.^{3, 5, 6} The FDA labels, including Ozempic's and Mounjaro's, set out those risks. Talk them through with your prescriber before starting or switching, but if a warning below tells you to stop the drug, don't wait for that conversation. This is not every risk; each brand-name drug comes with a Medication Guide, and the full labels are linked in the sources.

Ruled out on all six labels. Each of the six labels (Wegovy, Zepbound, Foundayo, the Ozempic pen, Ozempic tablets and Mounjaro) opens with a boxed warning on thyroid C-cell tumors. All six rule out people who have MEN 2, a personal or family history of MTC, or a past serious allergic reaction to the drug or anything in it. None is recommended for someone with severe gastroparesis, stomach emptying that is very slow.^{4, 34, 44, 53, 54, 55} Semaglutide caused these tumors in rats and mice, and tirzepatide in rats; it is not known whether either does in people, MTC included.^{34, 44, 53, 54, 55} Foundayo's drug, orforglipron, is inactive in rats and mice, so animal studies could not test it this way. Orforglipron is active at the human GLP-1 receptor, however, and Foundayo's label repeats the boxed warning and the MTC and MEN 2 rule. How much the rodent findings for this drug class mean for people has not been worked out.⁴

What differs from drug to drug:

• Wegovy (pen, HD or pill). Its label warns of possible harm to an unborn baby. If you take it for weight or heart risk, plan to stop it at least 2 months before trying to conceive, and stop it once you know you are pregnant. With MASH, make both choices with your prescriber, since the label allows use in pregnancy when the possible benefit justifies the risk. It can also raise your heart rate at rest, so your prescriber should check it; tell them if your heart races or pounds for several minutes. The pill is taken on an empty stomach with up to 4 ounces of water, at least 30 minutes before food, drinks or other pills, and isn't recommended while breastfeeding. One study found that semaglutide tablets increased exposure to levothyroxine, a thyroid medicine, by 33%, so if you take levothyroxine, your prescriber may monitor you more closely.⁴⁴
• Zepbound. Possible harm to an unborn baby means stopping it as soon as you know you are pregnant. Birth-control pills may work less well for 4 weeks after you start and after each dose increase, so use a non-pill method or add condoms or another barrier during those weeks. Warfarin is the example its label gives of a medicine to watch closely. It is for adults only.³⁴
• Foundayo. The same unborn-baby warning applies: stop it once you know you are pregnant, and use effective birth control while taking it. For birth-control pill users, the backup period is 30 days after starting and after each dose increase. Its label advises against it while breastfeeding and with severe liver impairment. Bring a full list of your medicines: the label says not to combine it with some that strongly block or speed up CYP3A4, a liver enzyme (ritonavir is one), and limits the simvastatin dose you can take with it. Food doesn't matter for this tablet, and it is for adults only.⁴
• Ozempic (pen or tablets). Its guide says to stop it at least 2 months before a planned pregnancy. If a pregnancy happens anyway, phone your prescriber instead of quitting on your own, since the label allows use in pregnancy when the possible benefit justifies the possible risk to the baby. The tablets have the Wegovy pill's empty-stomach rule, aren't advised while breastfeeding and showed the same levothyroxine effect. Ozempic is for adults only.^{53, 54}
• Mounjaro. If you become pregnant, phone your prescriber rather than stopping on your own; its label allows use in pregnancy when the possible benefit justifies the possible risk. The birth-control-pill and warfarin points match Zepbound's. It is approved from age 10, for type 2 diabetes.⁵⁵

Never share a multi-dose pen (Wegovy FlexTouch, the Zepbound or Mounjaro KwikPen, or the Ozempic pen), even after changing the needle: sharing can spread infections carried in blood.^{34, 44, 53, 55} With Zepbound vials, use a new needle and syringe for every injection, and never reuse or share needles or syringes.³⁴

Warnings on all six labels, with the signs to act on:^{4, 34, 44, 53, 54, 55}

• Pancreatitis (inflammation of the pancreas), which has been fatal in severe cases. Severe stomach pain that doesn't let up, with or without vomiting and sometimes spreading to your back, means stopping the drug and calling your prescriber right away.
• Serious allergic reactions. Stop the drug and get medical help right away if your face, lips, tongue or throat swell, if breathing or swallowing gets hard, or if you have a severe rash or itching, faint or feel dizzy, or your heart races.
• Gallbladder problems. Upper stomach pain, fever, yellowing of your skin or the whites of your eyes, or pale, clay-colored stools: tell your prescriber right away.
• Kidney damage from losing too much fluid, sometimes severe enough to need dialysis. If nausea, vomiting or diarrhea keeps going, call your prescriber right away and drink plenty of fluids. Report any stomach or bowel side effect that is severe or lasting.
• Low blood sugar. The risk is highest alongside insulin or a sulfonylurea (a type of diabetes pill), but it has also been reported in adults without type 2 diabetes taking Wegovy, Zepbound or Foundayo. Ask before your first dose how to recognize it (shaking, sweating, dizziness, confusion, a racing heart) and what to do.
• Worsening diabetic eye disease in people with type 2 diabetes. Report any change in your eyesight.
• Thyroid tumors. A neck lump or swelling, a hoarse voice, trouble swallowing or shortness of breath can be signs of one; tell your prescriber.
• Inhaling stomach contents under anesthesia or deep sedation, a rare problem. Before any planned procedure, let each doctor and dentist know you take one of these drugs.
• Effects on other pills. Because all six slow down how fast your stomach empties, they can change how other medicines taken by mouth are absorbed.

The Wegovy, Zepbound and Foundayo labels also advise against combining them with another GLP-1 drug, and that includes compounded semaglutide or tirzepatide, which a pharmacy makes for an individual patient's prescription.^{4, 34, 44, 56} An overdose needs help right away: call your prescriber or Poison Help at 1-800-222-1222, or get to an emergency room.^{4, 34, 44, 53, 54, 55}

After an Anthem denial: appeal rights by plan type

Start with the reason printed on the denial, because it decides your next step.⁵⁷ If records were missing, such as a BMI from more than 90 days before the request or proof of the six-month program, your prescriber can send them with an appeal.³ If the denial says your plan excludes the drug, two lines in Anthem's documents apply:

• Anthem's drug search says it pays nothing for drugs a plan specifically excludes, but that you may appeal that denial.²
• Anthem's exception process for drugs missing from a drug list does not apply when the use itself is excluded by your plan, and its criteria give weight loss as an example.⁵⁸

So you can still appeal an exclusion, but the exception process won't add a use your plan leaves out. Deadlines depend on the plan:

• A plan you bought yourself: file an internal appeal within 180 days of the denial notice.⁵⁷ If the denial turned on medical judgment, such as whether your records meet the criteria, you can then ask for an outside (external) review. HealthCare.gov's list of denials that qualify for that review doesn't include a plain refusal because your plan leaves the benefit out.⁵⁹
• A plan through work: use the deadline and steps in your denial letter.
• Anthem Medicare Advantage: if the drug isn't on your plan's list but is prescribed for a use Part D covers, such as Zepbound for sleep apnea or Wegovy for heart risk, your prescriber can ask the plan for an exception, with a statement of the medical reason.^{45, 60} To appeal a denial, ask within 65 days of the denial notice.⁶⁰ An appeal can't add weight-loss coverage that your plan's benefits leave out, and Medicare's GLP-1 Bridge has no appeals, only resubmission by your prescriber.^{13, 42}
• Anthem Medicaid: if your Anthem plan made the decision, as HealthKeepers Plus does with its form in Virginia, you have 60 days from the notice to appeal to the plan. After that, you can ask for a state fair hearing.^{18, 61} In California, Medi-Cal Rx makes the drug decision, so you ask the state for a State Hearing, generally within 90 days of its notice. If you were taking a GLP-1 on or before January 1, 2026, asking within 10 days can keep it coming while you wait, though not past the end of your current approval.¹⁷ For other states, see Medicaid appeals and fair hearings.

Our prior authorization guide walks through each step.

Buying Wegovy or Zepbound when your plan leaves them out

When a plan excludes these drugs, Anthem pays nothing toward them, so you would pay the full price.² The drugmakers sell the FDA-approved drugs directly to people paying cash. As of October 3, 2026, NovoCare Pharmacy charges $349 a month (one box of four pens) for Wegovy pens up to 2.4 mg and $399 for Wegovy HD. Patients new to the Wegovy savings offer or NovoCare Pharmacy pay $199 a month instead for their first two monthly fills of 0.25 or 0.5 mg, through December 31, 2026. Wegovy pills cost $149 to $299 a month, the $149 being the 1.5 mg starting dose.⁶²

As of October 3, 2026, LillyDirect charges $299 per 28-day supply of Zepbound vials or KwikPens at the 2.5 mg starting dose and $399 at 5 mg. Higher doses cost $449 if each refill comes within 45 days, and $499 to $699 otherwise; needles or syringes are extra.^{63, 64} For KwikPens, these prices come through a Lilly self-pay card that allows up to 11 fills a year and ends December 31, 2026.⁶³

People in Medicare or Medicaid can pay these cash prices too, as long as no insurance is billed, and the money doesn't count toward a deductible or out-of-pocket limit.^{63, 65} If your Anthem plan does cover one of these drugs, the makers' copay cards can lower your share, but they exclude anyone in Medicare, Medicaid or another government plan.^{62, 63} For every price with its conditions, see our page on GLP-1 prices without insurance, which also shows who can use which offer, by type of coverage. See also Foundayo's cash prices and paying with an HSA, FSA or CareCredit.

With type 2 diabetes, check your plan before paying cash for anything: the Ozempic pen is on all of Anthem's standard, small-group and individual drug lists, and Anthem's criteria allow it and Mounjaro for that diagnosis with prior authorization.^{1, 8, 10, 12}

Compounded drugs and PlexusDx's programs

Compounded semaglutide and tirzepatide are not FDA-approved: FDA does not review them before sale for safety, effectiveness or quality.⁶⁶ FDA advises using a compounded drug only when an FDA-approved one can't meet the patient's medical needs, and its guidance says a lower price alone doesn't justify a compounded copy of an approved drug.^{56, 66} A BE flag or an Anthem denial is not a medical need, so neither one is a reason to switch to a compounded drug.

As of May 31, 2026, FDA had received 990 reports of health problems (adverse events) in people using compounded semaglutide and more than 730 for compounded tirzepatide. FDA notes that it can't always tell whether the drug caused a reported problem or other factors contributed. It also has reports, some involving a hospital stay, that may be related to dosing mistakes with compounded semaglutide injections. Other reports it has received may be related to compounded semaglutide or tirzepatide prescribed beyond the approved labels: larger doses, more frequent doses or faster dose increases.⁶⁶

Many of the reported problems resemble the side effects of the approved drugs, FDA says, and there are probably more than reported, since state-licensed pharmacies other than outsourcing facilities aren't required to send FDA these reports.⁶⁶ Compounded products come with no FDA-approved label or Medication Guide, so if a prescriber suggests one, go through the risks above with them and see how to vet a compounded-drug provider.⁶⁶

As of October 19, 2026, the compounded GLP-1 programs offered by PlexusDx, which publishes this page, are cash pay and not billed to Anthem or any other insurer (see PlexusDx's Terms of Service). For that reason, they can't get you Anthem coverage or Medicare's $50 Bridge price. They are for adults 18 or older. Every PlexusDx GLP-1 plan follows the same rules at Lone Star: a BMI of 25 is the minimum for a first course, and 22 for a person who took a GLP-1 drug during the previous two months. The starting minimum sits under the 30, or 27 with a weight-related illness, that Wegovy's and Zepbound's labels and Anthem's criteria above use, so a new patient in between would be treated off-label. The intake screens for gallbladder disease, eating disorders, pancreatitis and thyroid cancer, among other things, but has no question on diabetic retinopathy, an upcoming procedure under sedation, or allergy to B12 or glycine (all of its questions are in our provider guide).

PlexusDx itself is not a medical practice or a pharmacy. It uses only state-licensed 503A compounding pharmacies. Federal law does not require pharmacies like these to report adverse events to FDA.^{56, 66}

U.S.-licensed clinicians from Lone Star Virtual Health, PlexusDx's provider team, decide whether to prescribe, after reviewing each person's medical history, and confirm final eligibility. PlexusDx does not sell or ship brand-name medications. If you would prefer a brand-name, FDA-approved medication, your provider may write a prescription you can fill at the pharmacy of your choice; Anthem's rules on this page apply to that prescription like any other. FDA's test above applies to PlexusDx's compounded programs as well. Lone Star Virtual Health told PlexusDx that its physicians must tailor the reason for a compounded drug to each patient, chart it, and tell the patient, including that the compounded drug is not FDA-approved; it has no one-size reason, and any argument from added B12, B6 or glycine has to stand on the patient's own clinical needs. As explained above, an Anthem denial is not a medical need.

If your BMI is below the levels Anthem's criteria and the drug trials used (30, or 27 with a weight-related condition), talk with your own doctor before you look at any drug outside your plan, whether it comes from a drugmaker, a pharmacy or an online program. PlexusDx is one of those programs. Our page on GLP-1s if you're not obese or overweight explains what applies to you.^{3, 34}

Sources

1. National Drug List, Three Tier Drug Plan (current as of August 1, 2026), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
2. Essential Drug List 3-Tier: drug search results for Wegovy (formulary effective October 1, 2026), Anthem Blue Cross and Blue Shield, via Formulary Navigator, accessed October 3, 2026.
3. Wegovy (semaglutide) clinical criteria (September 16, 2026), Anthem, via Formulary Navigator, accessed October 3, 2026.
4. FOUNDAYO (orforglipron) tablets: prescribing information and Medication Guide, Eli Lilly and Company, via DailyMed, National Library of Medicine, accessed October 3, 2026.
5. Zepbound (tirzepatide) clinical criteria (September 16, 2026), Anthem, via Formulary Navigator, accessed October 3, 2026.
6. Foundayo (orforglipron) clinical criteria (September 16, 2026), Anthem, via Formulary Navigator, accessed October 3, 2026.
7. 2025 Georgia Small Group Four Tier Select Drug List (current as of December 1, 2025), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
8. 2026 Georgia Small Group Four Tier Select Drug List (current as of October 1, 2026), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
9. 2027 Georgia Small Group Four Tier Select Drug List (current as of January 1, 2027), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
10. 2026 Georgia Individual Four Tier Select Drug List (current as of October 1, 2026), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
11. 2027 Georgia Individual Four Tier Select Drug List (current as of January 1, 2027), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
12. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist and GIP/GLP-1 Receptor Agonist clinical criteria (September 14, 2026), Anthem, via Formulary Navigator, accessed October 3, 2026.
13. 42 U.S. Code § 1395w-102, Prescription drug benefits, Legal Information Institute, Cornell Law School, accessed October 3, 2026.
14. 42 U.S. Code § 1396r-8, Payment for covered outpatient drugs, Legal Information Institute, Cornell Law School, accessed October 3, 2026.
15. 42 CFR § 423.104, Requirements related to qualified prescription drug coverage, Legal Information Institute, Cornell Law School, accessed October 3, 2026.
16. Medicare GLP-1 Bridge, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
17. Changes to GLP-1 Drug Coverage, Effective January 1, 2026 (member notice), Medi-Cal Rx, California Department of Health Care Services, accessed October 3, 2026.
18. Weight Loss Management Prior Authorization (PA) Form (September 2026), Anthem HealthKeepers Plus (HealthKeepers, Inc.), accessed October 3, 2026.
19. Our Companies, Elevance Health, accessed October 3, 2026.
20. National Drug List, Three Tier Drug Plan, California DMHC fully insured (current as of September 1, 2026), Anthem Blue Cross, accessed October 3, 2026.
21. Legal Disclosure, Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
22. Health Insurance Marketplace Plans from Ambetter Health, Centene Corporation, accessed October 3, 2026.
23. Drug List (pharmacy information), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
24. Prescription Medications to Treat Overweight & Obesity (last reviewed June 2024), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), accessed October 3, 2026.
25. Drug List (Georgia), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
26. Drug List (California), Anthem Blue Cross, accessed October 3, 2026.
27. New York Drug List, Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
28. IMCIVREE (setmelanotide) injection: prescribing information (revised April 2026), Rhythm Pharmaceuticals, via DailyMed, National Library of Medicine, accessed October 3, 2026.
29. California National Drug List (JAA), Three Tier Drug Plan (current as of September 1, 2026), Anthem Blue Cross, accessed October 3, 2026.
30. 2026 Connecticut Four Tier National Drug List, fully insured (current as of September 1, 2026), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
31. 2027 New York Three Tier National Drug List, fully insured (current as of January 1, 2027), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
32. National Drug List, Three Tier Drug Plan, California CDI fully insured (current as of September 1, 2026), Anthem Blue Cross, accessed October 3, 2026.
33. Self-insured plan (glossary), HealthCare.gov, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
34. ZEPBOUND (tirzepatide) injection: prescribing information and Medication Guide, Eli Lilly and Company, via DailyMed, National Library of Medicine, accessed October 3, 2026.
35. National Drug List, Closed Formulary (current as of August 1, 2026), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
36. Generic Premium Drug List, Three Tier Drug Plan (current as of August 1, 2026), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
37. Drug List (Connecticut), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
38. 2024 Essential Drug List, Three Tier Drug Plan, Connecticut fully insured (current as of April 1, 2026), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
39. California Four Tier Essential Drug List, DMHC (current as of April 1, 2025), Anthem Blue Cross, accessed October 3, 2026.
40. Drug List (Maine), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
41. Medicare Part D Prescription Drug Plans, Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
42. Medicare GLP-1 Bridge: Information for Providers, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
43. Definition & Facts of NAFLD & NASH (last reviewed April 2021), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), accessed October 3, 2026.
44. WEGOVY (semaglutide) injection and tablets: prescribing information and Medication Guide, Novo Nordisk, via DailyMed, National Library of Medicine, accessed October 3, 2026.
45. Medicare GLP-1 Bridge: Information for Part D Plans, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
46. 2026 GRS Premier Prior Authorization Criteria (effective October 1, 2026), Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
47. Anthem Medicare Preferred (PPO) with Senior Rx Plus 2026 Formulary (current as of October 1, 2026), Anthem Blue Cross, accessed October 3, 2026.
48. Weight loss drugs, Medicare.gov, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
49. GLP-1 Coverage Considerations (November 14, 2025), Anthem Blue Cross (Medi-Cal provider communication), accessed October 3, 2026.
50. Medi-Cal Rx Member Portal, Medi-Cal Rx, California Department of Health Care Services, accessed October 3, 2026.
51. Employer Pharmacy Information, Anthem Blue Cross and Blue Shield, accessed October 3, 2026.
52. GLP-1s and weight loss 101 (October 24, 2025), CarelonRx, an Elevance Health company, accessed October 3, 2026.
53. OZEMPIC (semaglutide) injection: prescribing information and Medication Guide, Novo Nordisk, via DailyMed, National Library of Medicine, accessed October 3, 2026.
54. RYBELSUS and OZEMPIC (semaglutide) tablets: prescribing information and Medication Guide, Novo Nordisk, via DailyMed, National Library of Medicine, accessed October 3, 2026.
55. MOUNJARO (tirzepatide) injection: prescribing information and Medication Guide, Eli Lilly and Company, via DailyMed, National Library of Medicine, accessed October 3, 2026.
56. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act (guidance, January 2018), U.S. Food and Drug Administration, accessed October 3, 2026.
57. Internal appeals, HealthCare.gov, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
58. Non-Formulary Prescription Request (clinical criteria), Anthem and CarelonRx, via Formulary Navigator, accessed October 3, 2026.
59. External Review, HealthCare.gov, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
60. Appeals in a Medicare drug plan, Medicare.gov, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
61. 42 CFR § 438.402, General requirements (Medicaid managed care appeals), Legal Information Institute, Cornell Law School, accessed October 3, 2026.
62. Wegovy (semaglutide) Cost, Coverage, & Savings Resources, Novo Nordisk (NovoCare), accessed October 3, 2026.
63. Zepbound full terms and conditions, Eli Lilly and Company, accessed October 3, 2026.
64. Zepbound, Eli Lilly and Company (LillyDirect), accessed October 3, 2026.
65. Savings Offer Program for Wegovy (semaglutide), Novo Nordisk (NovoCare), accessed October 3, 2026.
66. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, U.S. Food and Drug Administration, accessed October 3, 2026.

How we made this page

Anthem's answer to this question is a code printed beside each drug on its drug lists. Its 14 state pages link 245 of those lists in English, and four sets of clinical criteria add the rules. A script tallied the codes for every GLP-1 drug on each list as posted on October 3, 2026, and AI tools drafted the text and the approval table from those lists and the other sources above. The page leaves out three lists written for single named employers.

Besides Anthem's lists and criteria, the main sources are Anthem's California and Virginia Medicaid documents, Medi-Cal Rx's notice, two Anthem group Medicare documents and the federal rules on Part D and appeals. They also include CMS, Medicare.gov, HealthCare.gov, NIDDK, seven FDA drug labels, FDA's compounding pages, and Lilly's and NovoCare's price pages. A script compared each quoted passage with the document it came from as retrieved on October 3, 2026, and AI reviewers then compared each statement with its source, in rounds. Matching text to documents is machine checking, not a clinician's or a lawyer's review, and it is not an opinion on how Anthem will handle your claim. What the page says about PlexusDx is our own information, checked against PlexusDx's records as of October 19, 2026, which is why it carries no source number.

We could not see any member's plan documents, Anthem's member-only prices or its individual Medicare Advantage drug lists, so the page explains how to check them. An earlier PlexusDx post sat at this address. Its copay figures, approval times and "specialty drug" label had no support in Anthem's documents, and its claims about compounded semaglutide conflicted with FDA's. It also quoted PlexusDx prices and service claims that this page does not repeat. None of its text or prices was kept.

Anthem, HealthKeepers, Elevance Health, CarelonRx, Blue Cross and Blue Shield and the drug names on this page belong to their owners and appear only to identify them; none of these companies reviewed or endorsed this page. Jay Hastings reviewed and approved this version on October 19, 2026. Dr. Asad K. Niazi, MD, MPH, reviewed the medical content on October 17, 2026. He is co-founder and CEO of Lone Star Virtual Health, the company that provides PlexusDx's prescribing clinicians, so he has a business relationship with PlexusDx. PlexusDx sells compounded GLP-1 treatment, so we have a financial interest in this topic. Our editorial policy covers corrections and how pages like this one are made.